Google
Trusted Resources: News & Events
Latest announcements and gatherings
Sickle cell patients, families and doctors face a ‘fight for everything’
Francesca Valentine is gearing up for a fight with her insurance company over Endari, the new FDA-approved drug, which will likely be on the market in January. Endari is a highly refined version of a nutritional supplement called L-Glutamine, which has been shown to relax the stiff, sickle-shaped red blood cells of people with the disease. It’s the first of a number of new drugs in the pipeline and will cost about $3,300 per month for the average adult.
But many insurers plan to restrict how the drug covered. Several, including the Valentines’ Blue Cross Blue Shield’s Federal Employee Program, will cover Endari only if patients have “failed first” at other treatments, including blood transfusions and hydroxyurea (the only other drug available to treat sickle cell), even though in studies Endari appeared to be of benefit when given in conjunction with other treatments.
+myBinderRelated Content
-
Testing newbornsSickle cell disease is a hereditary dise...
-
Caregivers and Sickle Cell DiseaseCaregivers are responsible for the physi...
-
Camp New Hope 2022Camp New Hope is a seven-day; six-night ...
-
Matteson girl, 8, with sickle cell hosts party, blood drive to help othersA young Matteson girl who is bat...
-
Stigmatization of Sickle Cell Disease – Selina Olwenda-Chairperson Children Sickle Cell Foundationhttps://www.youtube.com/watch?time_conti...
-
How a Man and Woman, Both with a Sickle Cell Anemia Mutation, Had a Healthy ChildA man and woman who are both carriers of...
-
Listening to Sickle Cell Patients is Crucial During a CrisisI recently was admitted to the hospital ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.